TRVI

Trevi Therapeutics, Inc. (TRVI) - 10-K Summary

Business Context and Reporting Period

Company: Trevi Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Trevi is a clinical-stage biopharmaceutical company focused on developing Haduvio (oral nalbuphine ER), a kappa agonist and mu antagonist (KAMA), for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The company has no approved products and has not generated any product revenue.

Key Financial Metrics

Note: The company had no debt outstanding as of December 31, 2024, having fully repaid its Silicon Valley Bank term loan in May 2023.

Material Changes vs. Prior Period

• Increased R&D Spend: R&D expenses increased by $15.7 million (66.3%) to $39.4 million, driven by the Phase 2b CORAL trial (IPF), Phase 2a RIVER trial (RCC), Human Abuse Potential (HAP) study, and Phase 1b TIDAL study.
• Capital Raise: In December 2024, the company completed a registered direct offering raising approximately $50.0 million gross proceeds. Additionally, $14.6 million was raised via an at-the-market (ATM) sales agreement.
• Net Loss Expansion: Net loss increased by $18.8 million year-over-year, primarily due to higher clinical development costs.
• Positive Clinical Data: Announced positive topline data in March 2025 for the Phase 2a RIVER trial (RCC) and December 2024 for the HAP study.

Guidance, Outlook, and Risks

Clinical Outlook:

• IPF Program: Enrollment for the Phase 2b CORAL trial was completed in February 2025; topline results are expected in Q2 2025. The company plans to request an End-of-Phase 2 meeting with the FDA in 2025 and initiate a Phase 3 program in H1 2026, subject to CORAL results.
• RCC Program: Following positive Phase 2a RIVER data, the company is designing the next trial to determine dose response for a pivotal study.
• Non-IPF ILD Program: Planning a Phase 2 trial, contingent on positive CORAL data.

Liquidity: As of December 31, 2024, the company held $107.6 million in cash and marketable securities. Management believes this is sufficient to fund operations into the second half of 2026. No committed external funding sources exist.

Key Risks:

• Single Product Dependence: The company relies entirely on the success of Haduvio.
• Regulatory Uncertainty: Haduvio is an opioid-based therapy; the company faces risks regarding FDA approval pathways (Section 505(b)(2)) and potential scheduling as a controlled substance, though HAP data suggests a lower abuse potential.
• Capital Requirements: Substantial additional funding will be required to complete Phase 3 trials and commercialization. Failure to raise capital could force delays or abandonment of programs.
• Third-Party Reliance: The company relies on a single supplier for the active pharmaceutical ingredient (nalbuphine hydrochloride) and third-party CROs for clinical trials.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "second half of 2026" funding estimate against current burn rates and potential clinical delays.
• Phase 2b CORAL Results: Monitor the Q2 2025 topline data release, as this is the primary catalyst for initiating Phase 3 trials.
• Regulatory Pathway: Confirm the FDA's stance on the Section 505(b)(2) pathway and the final determination on whether Haduvio will be classified as a controlled substance.
• Supply Chain: Assess the stability of the single-source supply agreement for nalbuphine hydrochloride.
• Dilution Risk: Review the impact of outstanding warrants (approx. 32.9 million shares) and potential future equity raises on shareholder value.